Literature DB >> 18591881

Weight gain during the treatment of thyrotoxicosis using conventional thyrostatic treatment.

M S Rathi1, J N Miles, P E Jennings.   

Abstract

OBJECTIVE: Patients often lose considerable weight prior to the diagnosis of thyrotoxicosis. Regaining weight with treatment of thyrotoxicosis until hormone levels normalise is expected. This study was aimed to determine whether patients continued to put on weight once they were euthyroid. STUDY DESIGN AND
METHOD: The records of 60 consecutive euthyroid patients were studied. All patients were rendered euthyroid on thyrostatic medication alone. Patients on a block and replacement regime, those who developed transient hypothyroidism on treatment or other diagnoses causing weight gain were excluded.
RESULTS: The mean age of study group was 46.13 yr (21-73). Male:female ratio was 5:55. 36 (60%) patients had diagnosis of Graves' disease. On initial presentation weight was 67.75 kg (SEM 2.1) with body mass index (BMI) of 25.8. Patients took 6.7 months (mean) to become euthyroid. Mean weight when euthyroid was 71.61 kg (range 46-125). Even after becoming euthyroid, patient continued to gain weight at 3, 6, and 9 months and mean weight gain was 2.04 kg (SD 18.14) at 3 months (p=0.003). This weight gain was not related to patients' age, gender, BMI, duration or dose of treatment required to achieve euthyroidism. Diagnosis of Graves' disease and non-smoking status independently predicted weight gain.
CONCLUSION: We have demonstrated that patients with thyrotoxicosis continue to gain weight for at least 6 months even after becoming euthyroid. Patients with Graves' disease were more likely to gain weight compared to others. Smokers gained least weight. Preventing this weight gain warrants further investigation.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18591881     DOI: 10.1007/BF03346398

Source DB:  PubMed          Journal:  J Endocrinol Invest        ISSN: 0391-4097            Impact factor:   4.256


  12 in total

1.  Long-term weight changes in treated hyperthyroid and hypothyroid patients.

Authors:  J Pears; R T Jung; A Gunn
Journal:  Scott Med J       Date:  1990-12       Impact factor: 0.729

2.  Body weight and body composition changes after treatment of hyperthyroidism.

Authors:  L Lönn; K Stenlöf; M Ottosson; A K Lindroos; E Nyström; L Sjöström
Journal:  J Clin Endocrinol Metab       Date:  1998-12       Impact factor: 5.958

3.  Nicotine as a psychoactive drug: appetite regulation.

Authors:  N E Grunberg
Journal:  Psychopharmacol Bull       Date:  1986

Review 4.  Neuropeptide regulation of appetite and weight.

Authors:  J E Morley
Journal:  Endocr Rev       Date:  1987-08       Impact factor: 19.871

5.  Thyroid function and energy intake during weight gain following treatment of hyperthyroidism.

Authors:  M Abid; C J Billington; F Q Nuttall
Journal:  J Am Coll Nutr       Date:  1999-04       Impact factor: 3.169

6.  Dietary intake in thyrotoxicosis before and after adequate carbimazole therapy; the impact of dietary advice.

Authors:  S Alton; B P O'Malley
Journal:  Clin Endocrinol (Oxf)       Date:  1985-11       Impact factor: 3.478

Review 7.  Nicotinic receptor-mediated effects on appetite and food intake.

Authors:  Young-Hwan Jo; David A Talmage; Lorna W Role
Journal:  J Neurobiol       Date:  2002-12

8.  The relationship between the serum leptin concentrations of thyrotoxic patients during treatment and their total fat mass is different from that of normal subjects.

Authors:  T Zimmermann-Belsing; M Dreyer; J J Holst; U Feldt-Rasmussen
Journal:  Clin Endocrinol (Oxf)       Date:  1998-11       Impact factor: 3.478

9.  Weight gain following treatment of hyperthyroidism.

Authors:  J Dale; J Daykin; R Holder; M C Sheppard; J A Franklyn
Journal:  Clin Endocrinol (Oxf)       Date:  2001-08       Impact factor: 3.478

10.  Long-term weight regulation in treated hyperthyroid and hypothyroid subjects.

Authors:  B J Hoogwerf; F Q Nuttall
Journal:  Am J Med       Date:  1984-06       Impact factor: 4.965

View more
  3 in total

1.  Relationship between thyroid dysfunction and body weight: a not so evident paradigm.

Authors:  Mónica Ríos-Prego; Luis Anibarro; Paula Sánchez-Sobrino
Journal:  Int J Gen Med       Date:  2019-08-23

2.  Modulating gut microbiota in a mouse model of Graves' orbitopathy and its impact on induced disease.

Authors:  Sajad Moshkelgosha; Hedda Luise Verhasselt; Giulia Masetti; Anja Eckstein; Marian Ludgate; Utta Berchner-Pfannschmidt; Danila Covelli; Filippo Biscarini; Mareike Horstmann; Anke Daser; Astrid M Westendorf; Christoph Jesenek; Svenja Philipp; Salvador Diaz-Cano; J Paul Banga; Daryn Michael; Sue Plummer; Julian R Marchesi
Journal:  Microbiome       Date:  2021-02-16       Impact factor: 14.650

3.  Weight Gain and Body Composition Changes during the Transition of Thyroid Function in Patients with Graves' Disease Undergoing Radioiodine Treatment.

Authors:  Zhenqin Cai; Qiyu Chen; Yan Ling
Journal:  Int J Endocrinol       Date:  2022-07-18       Impact factor: 2.803

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.